Enalare Therapeutics Inc., dedicated to developing novel therapies for patients suffering from acute respiratory conditions, announced the completed formation of the clinical stage biopharmaceutical company’s scientific advisory board.
If you are not happy with the results below please do another search
50 search results for:
The Trump administration plans to release Covid-19 vaccine doses it had been holding back for second shots and will urge states to offer them to all Americans over age 65, according to U.S. Department of Health and Human Services Secretary Alex Azar.
Biond Biologics Ltd. forged an exclusive global license agreement, potentially worth more than $1 billion, with French drugmaker Sanofi for the development and commercialization of the Israeli company’s BND-22 cancer drug.
British drugmaker GSK and U.S.-based Vir Biotechnology will evaluate a second antibody-based treatment in patients with mild to moderate Covid-19 in an early-stage to mid-stage trial.
Roche presented updated data confirming the Swiss drugmaker’s immunotherapy Tecentriq, used in combination with Avastin, substantially improves overall survival in people with the most common form of liver cancer.
BeiGene Ltd. will partner with Swiss firm Novartis AG to develop, manufacture and commercialize the China-based biotechnology company’s cancer drug tislelizumab.
Immunity from Moderna Inc.’s Covid-19 vaccine should last at least a year, the company said at the J.P. Morgan Healthcare conference.
A roundup of scientific studies on the novel coronavirus and efforts to find treatments and vaccines includes research on Covid-19 patients who still have symptoms 6 months after falling ill.
As many as eight gorillas at the San Diego Zoo Safari Park were presumed to have contracted Covid-19 from a human handler after one of the animals tested positive, marking the first known transmission of the virus to apes, zoo officials said.
RNAi-focused Atalanta Therapeutics launched with $110 million in combined Series A funding and collaboration deals with Genentech and Biogen to address diseases related to the central nervous system, including Huntington’s, Alzheimer’s and Parkinson’s diseases.